nivimedone sodium

Nivimedone sodium (BRL 10833) is an orally active small molecule mast cell stabilizer originally developed by Beecham Research Laboratories (now part of GSK). Chemically identified as the sodium salt of 5,6-dimethyl-2-nitroindane-1,3-dione, it was investigated in the 1970s as a prophylactic treatment for bronchial asthma and allergic rhinitis. Its mechanism of action is analogous to disodium cromoglycate (DSCG), involving the stabilization of mast cell membranes to inhibit the release of inflammatory mediators such as histamine. Clinical studies demonstrated that oral administration of nivimedone could reduce the requirement for bronchodilators and improve peak expiratory flow rates in atopic asthmatic patients. Despite showing clinical benefit in early trials, development was ultimately discontinued, and the drug was never brought to market.

Other names

sodium nivimedonenivimedone5,6-dimethyl-2-nitroindane-1,3-dione sodium salt